
BigHat Biosciences
@BigHatBio
Followers
989
Following
263
Media
160
Statuses
343
AI-enabled experimental platform to accelerate antibody engineering
San Mateo, CA
Joined November 2019
We’re thrilled to share that @ryan_henrici, our VP of Discovery Medicine, has been selected as a recipient of @penn_state's 2025 Alumni Achievement Award!. This prestigious honor celebrates Ryan’s exceptional contributions to science and medicine—from his early academic
0
0
6
We are excited to share an important leadership update at BigHat Biosciences. @peytongreenside has stepped into the role of CEO, bringing deep scientific expertise, strategic vision, and a strong commitment to our mission to develop better biologics through ML-guided design. We.
0
3
20
BigHat’s machine learning team is excited to share its latest paper, in collaboration with the Gordon Wilson Lab at @nyuniversity, “Bayesian Optimization of Antibodies Informed by a Generative Model of Evolving Sequences,” which was accepted for publication at the prestigious.
0
2
9
BigHat is excited to kick off 2025 with a productive @jpmorgan Healthcare Conference 2025!. On Tuesday, January 14, 2025 our CEO, @MarkDePristo, will speak on the Next in Tech Bio | Computational Strategies for Drug Discovery panel (⏰ 7:00PM @ 📍 Benchling) and CBO, Liz
0
1
8
BigHat’s VP of Discovery Medicine, @ryan_henrici, will be giving his invited talk "Machine Learning-guided Design of Logic Gated and Avidity-driven T Cell Engagers for Solid Malignancies” at the @AntibodyEngIC Conference on December 17th at 11 AM PST in San Diego. The talk will
0
1
1
Hunter Elliott, BigHat’s Sr. Director of Machine Learning, as well as @AlanNawzadAmin, from the @andrewgwils lab at @nyuniversity, will be presenting a paper titled, “Bayesian Optimization of Antibodies Informed by a Generative Model of Evolving Sequences” at the @NeurIPSConf
0
1
5
BigHat Biosciences is featured in @statnews today’s “Who to Know: 7 companies to watch in AI protein design.”. Read more about our work and how we’re advancing the field of next-generation biologics:
0
1
2
Today, we’re thrilled to announce that BigHat is developing a best-in-class ADC that combines our cutting-edge ML-guided antibody design platform with @Synaffix B.V. (“Synaffix”), a @LonzaGroup company’s (SWX:LONN) site-specific linker-payload technology. With these next-gen
0
0
6
We’re thrilled to announce that Charbel Eid, VP of Platform at BigHat Biosciences, will be giving an invited talk at the upcoming @LRIG_ORG event!. Charbel will be sharing insights into how BigHat is revolutionizing the development of next-generation antibody therapeutics through
0
1
2